Cellular and Molecular Life Sciences

, Volume 68, Issue 3, pp 353–368 | Cite as

The role of HLA-G in immunity and hematopoiesis

  • Edgardo D. Carosella
  • Silvia Gregori
  • Nathalie Rouas-Freiss
  • Joel LeMaoult
  • Catherine Menier
  • Benoit Favier
Multi-Author Review


The non-classical HLA class I molecule HLA-G was initially shown to play a major role in feto–maternal tolerance. Since this discovery, it has been established that HLA-G is a tolerogenic molecule which participates to the control of the immune response. In this review, we summarize the recent advances on (1) the multiple structures of HLA-G, which are closely associated with their role in the inhibition of NK cell cytotoxicity, (2) the factors that regulate the expression of HLA-G and its receptors, (3) the mechanism of action of HLA-G at the immunological synapse and through trogocytosis, and (4) the generation of suppressive cells through HLA-G. Moreover, we also review recent findings on the non-immunological functions of HLA-G in erythropoiesis and angiogenesis.


HLA-G ILT Dimers Immunological synapse Trogocytosis Regulatory cells Haematopoiesis Erythroid progenitors Angiogenesis 



Human leukocyte antigen G

NK cell

Natural killer cell


Immunological synapse


Immunoglobulin-like transcript





This work was supported by the Commissariat a l’energie atomique et aux energies alternatives (CEA).


  1. 1.
    Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED (1997) Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 94:11520–11525PubMedCrossRefGoogle Scholar
  2. 2.
    Carosella ED, Rouas-Freiss N, Paul P, Dausset J (1999) HLA-G: a tolerance molecule from the major histocompatibility complex. Immunol Today 20:60–62PubMedCrossRefGoogle Scholar
  3. 3.
    Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N (2008) HLA-G: from biology to clinical benefits. Trends Immunol 29:125–132PubMedCrossRefGoogle Scholar
  4. 4.
    Menier C, Rouas-Freiss N, Favier B, Lemaoult J, Moreau P, Carosella ED. (2010) Recent advances on the non-classical major histocompatibility complex class I HLA-G molecule. Tissue Antigens 75:201–206Google Scholar
  5. 5.
    Cantoni C, Verdiani S, Falco M, Pessino A, Cilli M, Conte R, Pende D, Ponte M, Mikaelsson MS, Moretta L, Biassoni R (1998) p49, a putative HLA class I-specific inhibitory NK receptor belonging to the Ig superfamily. Eur J Immunol 28:1980–1990PubMedCrossRefGoogle Scholar
  6. 6.
    Colonna M, Navarro F, Bellon T, Llano M, Samaridis J, Angman L, Cella M, Lopez-Botet M (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186:1809–1818PubMedCrossRefGoogle Scholar
  7. 7.
    Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O’Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A (1998) Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 160:3096–3100PubMedGoogle Scholar
  8. 8.
    Rajagopalan S, Long EO (1999) A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 189:1093–1100PubMedCrossRefGoogle Scholar
  9. 9.
    Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J (2008) Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 111:4862–4870PubMedCrossRefGoogle Scholar
  10. 10.
    Favier B, LeMaoult J, Rouas-Freiss N, Moreau P, Menier C, Carosella ED (2007) Research on HLA-G: an update. Tissue Antigens 69:207–211PubMedCrossRefGoogle Scholar
  11. 11.
    Juch H, Blaschitz A, Daxbock C, Rueckert C, Kofler K, Dohr G (2005) A novel sandwich ELISA for [alpha]1 domain based detection of soluble HLA-G heavy chains. J Immunol Methods 307:96–106PubMedCrossRefGoogle Scholar
  12. 12.
    Park GM, Lee S, Park B, Kim E, Shin J, Cho K, Ahn K (2004) Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 313:606–611PubMedCrossRefGoogle Scholar
  13. 13.
    Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Horejsi V, Goldman-Wohl D, Yagel S, Mandelboim O (2005) The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and β2-microglobulin-free HLA-G molecules. J Immunol 175:4866–4874PubMedGoogle Scholar
  14. 14.
    Ishitani A, Geraghty DE (1992) Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 89:3947–3951PubMedCrossRefGoogle Scholar
  15. 15.
    Kirszenbaum M, Moreau P, Gluckman E, Dausset J, Carosella E (1994) An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci USA 91:4209–4213PubMedCrossRefGoogle Scholar
  16. 16.
    Morales PJ, Pace JL, Platt JS, Langat DK, Hunt JS (2007) Synthesis of B2-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells. Immunology 122:179–188PubMedCrossRefGoogle Scholar
  17. 17.
    Moreau P, Carosella E, Teyssier M, Prost S, Gluckman E, Dausset J, Kirszenbaum M (1995) Soluble HLA-G molecule. An alternatively spliced HLA-G mRNA form candidate to encode it in peripheral blood mononuclear cells and human trophoblasts. Hum Immunol 43:231–236PubMedCrossRefGoogle Scholar
  18. 18.
    Paul P, Cabestre FA, Ibrahim EC, Lefebvre S, Khalil-Daher I, Vazeux G, Quiles RM, Bermond F, Dausset J, Carosella ED (2000) Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 61:1138–1149PubMedCrossRefGoogle Scholar
  19. 19.
    Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, Valter MM, Angelisova P, Horejsi V, Strominger JL (2002) Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci USA 99:16180–16185PubMedCrossRefGoogle Scholar
  20. 20.
    Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, Markel G, Goldman-Wohl D, Yagel S, Horejsi V, Levy O, Baniyash M, Mandelboim O (2003) Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 171:1343–1351PubMedGoogle Scholar
  21. 21.
    Clements CS, Kjer-Nielsen L, Kostenko L, Hoare HL, Dunstone MA, Moses E, Freed K, Brooks AG, Rossjohn J, McCluskey J (2005) Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci USA 102:3360–3365PubMedCrossRefGoogle Scholar
  22. 22.
    Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, Arase H, Tsumoto K, Kumagai I, Kohda D, Maenaka K (2006) Efficient leukocyte ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 281:10439–10447PubMedCrossRefGoogle Scholar
  23. 23.
    Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A (2007) A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol 37:1924–1937PubMedCrossRefGoogle Scholar
  24. 24.
    Morales PJ, Pace JL, Platt JS, Phillips TA, Morgan K, Fazleabas AT, Hunt JS (2003) Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J Immunol 171:6215–6224PubMedGoogle Scholar
  25. 25.
    Rebmann V, LeMaoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H (2005) Report of the wet workshop for quantification of soluble HLA-G in Essen, 2004. Hum Immunol 66:853–863PubMedCrossRefGoogle Scholar
  26. 26.
    Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED (2000) Implication of HLA-G molecule in heart-graft acceptance. Lancet 355:2138PubMedCrossRefGoogle Scholar
  27. 27.
    Lila N, Amrein C, Guillemain R, Chevalier P, Latremouille C, Fabiani JN, Dausset J, Carosella ED, Carpentier A (2002) Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105:1949–1954PubMedCrossRefGoogle Scholar
  28. 28.
    Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N (2003) HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 81:199–252PubMedCrossRefGoogle Scholar
  29. 29.
    Ibrahim EC, Morange M, Dausset J, Carosella ED, Paul P (2000) Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones 5:207–218PubMedCrossRefGoogle Scholar
  30. 30.
    Gazit E, Sherf M, Balbin E, Muratov A, Goldstein I, Loewenthal R (2007) HLA-G expression is induced in Epstein–Barr virus-transformed B-cell lines by culture conditions. Hum Immunol 68:463–468PubMedCrossRefGoogle Scholar
  31. 31.
    Mouillot G, Marcou C, Zidi I, Guillard C, Sangrouber D, Carosella ED, Moreau P (2007) Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 68:277–285PubMedCrossRefGoogle Scholar
  32. 32.
    Yie SM, Li LH, Li GM, Xiao R, Librach CL (2006) Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum Reprod 21:46–51PubMedCrossRefGoogle Scholar
  33. 33.
    Sebti Y, Le Maux A, Gros F, De Guibert S, Pangault C, Rouas-Freiss N, Bernard M, Amiot L (2007) Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol 138:202–212PubMedCrossRefGoogle Scholar
  34. 34.
    Lefebvre S, Berrih-Aknin S, Adrian F, Moreau P, Poea S, Gourand L, Dausset J, Carosella ED, Paul P (2001) A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem 276:6133–6139PubMedCrossRefGoogle Scholar
  35. 35.
    Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, Carosella ED, Paul P (1999) IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 11:803–811PubMedCrossRefGoogle Scholar
  36. 36.
    Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells 26:212–222PubMedCrossRefGoogle Scholar
  37. 37.
    Zidi I, Guillard C, Marcou C, Krawice-Radanne I, Sangrouber D, Rouas-Freiss N, Carosella ED, Moreau P (2006) Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci 63:2669–2681PubMedCrossRefGoogle Scholar
  38. 38.
    Bamberger AM, Jenatschke S, Schulte HM, Loning T, Bamberger MC (2000) Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab 85:3932–3936PubMedCrossRefGoogle Scholar
  39. 39.
    Moreau P, Flajollet S, Carosella ED (2009) Nonclassical transcriptional regulation of HLA-G: an update. J Cell Mol Med 13:2973–2989Google Scholar
  40. 40.
    Brugiere O, Thabut G, Pretolani M, Krawice-Radanne I, Dill C, Herbreteau A, Poras I, Moreau P, Colombat M, Danel C, Dehoux M, Fournier M, Carosella ED, Rouas-Freiss N (2009) Immunohistochemical study of HLA-G expression in lung transplant recipients. Am J Transplant 9:1427–1438PubMedCrossRefGoogle Scholar
  41. 41.
    Holgate ST (2000) Epithelial damage and response. Clin Exp Allergy 30(Suppl 1):37–41PubMedCrossRefGoogle Scholar
  42. 42.
    Sheshgiri R, Rouas-Freiss N, Rao V, Butany J, Ramzy D, Krawice-Radanne I, Ross HJ, Carosella ED, Delgado DH (2008) Myocardial HLA-G reliably indicates a low risk of acute cellular rejection in heart transplant recipients. J Heart Lung Transplant 27:522–527PubMedCrossRefGoogle Scholar
  43. 43.
    Sheshgiri R, Rao V, Tumiati LC, Xiao R, Prodger JL, Badiwala M, Librach C, Delgado DH (2008) Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells. Circulation 118:S58–S64PubMedCrossRefGoogle Scholar
  44. 44.
    Szekeres-Bartho J, Halasz M, Palkovics T (2009) Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol 83:60–64PubMedCrossRefGoogle Scholar
  45. 45.
    Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8:726–736Google Scholar
  46. 46.
    Ivanova-Todorova E, Mourdjeva M, Kyurkchiev D, Bochev I, Stoyanova E, Dimitrov R, Timeva T, Yunakova M, Bukarev D, Shterev A, Tivchev P, Kyurkchiev S (2009) HLA-G expression is up-regulated by progesterone in mesenchymal stem cells. Am J Reprod Immunol 62:25–33PubMedCrossRefGoogle Scholar
  47. 47.
    Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P (2002) Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196:266–274PubMedCrossRefGoogle Scholar
  48. 48.
    Benson JR, Pitsinis V (2003) Update on clinical role of tamoxifen. Curr Opin Obstet Gynecol 15:13–23PubMedCrossRefGoogle Scholar
  49. 49.
    Klijn JG, Setyono-Han B, Foekens JA (2000) Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65:825–830PubMedCrossRefGoogle Scholar
  50. 50.
    He X, Dong DD, Yie SM, Yang H, Cao M, Ye SR, Li K, Liu J, Chen J (2010) HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann Surg Oncol 17:1459–1469PubMedCrossRefGoogle Scholar
  51. 51.
    Luque J, Torres MI, Aumente MD, Lozano JM, Garcia-Jurado G, Gonzalez R, Alvarez-Lopez MR, Arizon JM, Pena J (2006) sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation. Transpl Immunol 17:70–73PubMedCrossRefGoogle Scholar
  52. 52.
    Bahri R, Naji A, Menier C, Charpentier B, Carosella ED, Rouas-Freiss N, Durrbach A (2009) Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J Immunol 183:7054–7062PubMedCrossRefGoogle Scholar
  53. 53.
    LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED (2005) HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19:662–664PubMedGoogle Scholar
  54. 54.
    Lozano JM, Gonzalez R, Kindelan JM, Rouas-Freiss N, Caballos R, Dausset J, Carosella ED, Pena J (2002) Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. Aids 16:347–351PubMedCrossRefGoogle Scholar
  55. 55.
    Vlad G, Piazza F, Colovai A, Cortesini R, Della Pietra F, Suciu-Foca N, Manavalan JS (2003) Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals. Hum Immunol 64:483–489PubMedCrossRefGoogle Scholar
  56. 56.
    Aractingi S, Briand N, Le Danff C, Viguier M, Bachelez H, Michel L, Dubertret L, Carosella ED (2001) HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol 159:71–77PubMedGoogle Scholar
  57. 57.
    Khosrotehrani K, Le Danff C, Reynaud-Mendel B, Dubertret L, Carosella ED, Aractingi S (2001) HLA-G expression in atopic dermatitis. J Invest Dermatol 117:750–752PubMedCrossRefGoogle Scholar
  58. 58.
    Brenk M, Scheler M, Koch S, Neumann J, Takikawa O, Hacker G, Bieber T, von Bubnoff D (2009) Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+ CD25+ Foxp3+ T regulatory cells. J Immunol 183:145–154PubMedCrossRefGoogle Scholar
  59. 59.
    Lopez AS, Alegre E, Lemaoult J, Carosella E, Gonzalez A (2006) Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol Immunol 43:2151–2160Google Scholar
  60. 60.
    Fedoric B, Krishnan R (2008) Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunol Lett 120:49–56Google Scholar
  61. 61.
    Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, Mancini D, Suciu-Foca N (2003) High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11:245–258PubMedCrossRefGoogle Scholar
  62. 62.
    Gleissner CA, Dengler TJ (2009) Induction of ILT expression on nonprofessional antigen presenting cells: clinical applications. Hum Immunol 70:357–359PubMedCrossRefGoogle Scholar
  63. 63.
    Svajger U, Vidmar A, Jeras M (2008) Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ILT3 and ILT4. Int Immunopharmacol 8:997–1005PubMedCrossRefGoogle Scholar
  64. 64.
    Rizzo R, Ferrari D, Melchiorri L, Stignani M, Gulinelli S, Baricordi OR, Di Virgilio F (2009) Extracellular ATP acting at the P2X7 receptor inhibits secretion of soluble HLA-G from human monocytes. J Immunol 183:4302–4311PubMedCrossRefGoogle Scholar
  65. 65.
    Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL (1999) The human natural killer cell immune synapse. Proc Natl Acad Sci USA 96:15062–15067PubMedCrossRefGoogle Scholar
  66. 66.
    Orange JS (2008) Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 8:713–725Google Scholar
  67. 67.
    Favier B, Lemaoult J, Lesport E, Carosella ED (2010) ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J 24:689–699PubMedCrossRefGoogle Scholar
  68. 68.
    Orange JS, Harris KE, Andzelm MM, Valter MM, Geha RS, Strominger JL (2003) The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc Natl Acad Sci USA 100:14151–14156PubMedCrossRefGoogle Scholar
  69. 69.
    Colucci F, Rosmaraki E, Bregenholt S, Samson SI, Di Bartolo V, Turner M, Vanes L, Tybulewicz V, Di Santo JP (2001) Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms. J Exp Med 193:1413–1424PubMedCrossRefGoogle Scholar
  70. 70.
    Graham DB, Cella M, Giurisato E, Fujikawa K, Miletic AV, Kloeppel T, Brim K, Takai T, Shaw AS, Colonna M, Swat W (2006) Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J Immunol 177:2349–2355PubMedGoogle Scholar
  71. 71.
    Butler B, Kastendieck DH, Cooper JA (2008) Differently phosphorylated forms of the cortactin homolog HS1 mediate distinct functions in natural killer cells. Nat Immunol 9:887–897PubMedCrossRefGoogle Scholar
  72. 72.
    Vyas YM, Mehta KM, Morgan M, Maniar H, Butros L, Jung S, Burkhardt JK, Dupont B (2001) Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J Immunol 167:4358–4367PubMedGoogle Scholar
  73. 73.
    Almeida CR, Davis DM (2006) Segregation of HLA-C from ICAM-1 at NK cell immune synapses is controlled by its cell surface density. J Immunol 177:6904–6910PubMedGoogle Scholar
  74. 74.
    Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella E, LeMaoult J (2007) Trogocytosis-based generation of suppressive NK cells. EMBO J 26:1423–1433PubMedCrossRefGoogle Scholar
  75. 75.
    Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, Jones EY, van der Merwe PA, Kumagai I, Maenaka K (2003) Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 100:8856–8861PubMedCrossRefGoogle Scholar
  76. 76.
    Schleinitz N, March ME, Long EO (2008) Recruitment of activation receptors at inhibitory NK cell immune synapses. PLoS ONE 3:e3278PubMedCrossRefGoogle Scholar
  77. 77.
    Menier C, Prevot S, Carosella ED, Rouas-Freiss N (2009) Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. Hum Immunol 70:1006–1009Google Scholar
  78. 78.
    Lesport E, Baudhuin J, LeMaoult J, Sousa S, Doliger C, Carosella ED, Favier B (2009) Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. Hum Immunol 70:1000–1005PubMedCrossRefGoogle Scholar
  79. 79.
    Dietrich J, Cella M, Colonna M (2001) Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol 166:2514–2521PubMedGoogle Scholar
  80. 80.
    Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, Menier C, Dausset J, Guillet JG, Carosella ED, Rouas-Freiss N (1999) HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 11:1351–1356PubMedCrossRefGoogle Scholar
  81. 81.
    Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M (2002) A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168:4772–4780PubMedGoogle Scholar
  82. 82.
    Bona C, Robineaux R, Anteunis A, Heuclin C, Astesano A (1973) Transfer of antigen from macrophages to lymphocytes. II. Immunological significance of the transfer of lipopolysaccharide. Immunology 5:831–840Google Scholar
  83. 83.
    Davis DM (2007) Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol 7:238–243PubMedCrossRefGoogle Scholar
  84. 84.
    LeMaoult J, Caumartin J, Carosella ED (2007) Exchanges of membrane patches (trogocytosis) split theoretical and actual functions of immune cells. Hum Immunol 68:240–243PubMedCrossRefGoogle Scholar
  85. 85.
    Arnold PY, Davidian DK, Mannie MD (1997) Antigen presentation by T cells: T cell receptor ligation promotes antigen acquisition from professional antigen-presenting cells. Eur J Immunol 27:3198–3205PubMedCrossRefGoogle Scholar
  86. 86.
    Huang J-F, Yang Y, Sepulveda H, Shi W, Hwang I, Peterson PA, Jackson MR, Sprent J, Cai Z (1999) TCR-mediated internalization of peptide–MHC complexes acquired by T cells. Science 286:952–954PubMedCrossRefGoogle Scholar
  87. 87.
    Hudrisier D, Riond J, Mazarguil H, Gairin JE, Joly E (2001) Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. J Immunol 166:3645–3649PubMedGoogle Scholar
  88. 88.
    Espinosa E, Tabiasco J, Hudrisier D, Fournie J-J (2002) Synaptic transfer by human {gamma}{delta} T cells stimulated with soluble or cellular antigens. J Immunol 168:6336–6343PubMedGoogle Scholar
  89. 89.
    Batista FD, Iber D, Neuberger MS (2001) B cells acquire antigen from target cells after synapse formation. Nature 411:489–494PubMedCrossRefGoogle Scholar
  90. 90.
    Carlin LM, Eleme K, McCann FE, Davis DM (2001) Intercellular transfer and supramolecular organization of human leukocyte antigen C at inhibitory natural killer cell immune synapses. J Exp Med 194:1507–1517PubMedCrossRefGoogle Scholar
  91. 91.
    Herrera OB, Golshayan D, Tibbott R, Ochoa FS, James MJ, Marelli-Berg FM, Lechler RI (2004) A novel pathway of alloantigen presentation by dendritic cells. J Immunol 173:4828–4837PubMedGoogle Scholar
  92. 92.
    Vanherberghen B, Andersson K, Carlin LM, Nolte-’t Hoen EN, Williams GS, Hoglund P, Davis DM (2004) Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proc Natl Acad Sci USA 101:16873–16878PubMedCrossRefGoogle Scholar
  93. 93.
    Hudrisier D, Riond J, Garidou L, Duthoit C, Joly E (2005) T cell activation correlates with an increased proportion of antigen among the materials acquired from target cells. Eur J Immunol 35:2284–2294PubMedCrossRefGoogle Scholar
  94. 94.
    Tatari-Calderone Z, Semnani RT, Nutman TB, Schlom J, Sabzevari H (2002) Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction. J Immunol 169:6162–6169PubMedGoogle Scholar
  95. 95.
    Xiang J, Huang H, Liu Y (2005) A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol 174:7497–7505PubMedGoogle Scholar
  96. 96.
    Game DS, Rogers NJ, Lechler RI (2005) Acquisition of HLA-DR and costimulatory molecules by T cells from allogeneic antigen presenting cells. Am J Transplant 7:1614–1625CrossRefGoogle Scholar
  97. 97.
    LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella E (2007) Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 109:2040–2048PubMedCrossRefGoogle Scholar
  98. 98.
    HoWangYin KY, Alegre E, Daouya M, Favier B, Carosella ED, LeMaoult J (2010) Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci 67:1133–1145PubMedCrossRefGoogle Scholar
  99. 99.
    Bacchetta R, Gambineri E, Roncarolo MG (2007) Role of regulatory T cells and FOXP3 in human diseases. J Allergy Clin Immunol 120:227–235 quiz 236–237PubMedCrossRefGoogle Scholar
  100. 100.
    Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445:771–775PubMedCrossRefGoogle Scholar
  101. 101.
    Roncarolo MG, Gregori S (2008) Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 38:925–927PubMedCrossRefGoogle Scholar
  102. 102.
    Battaglia M, Roncarolo MG (2009) The Tregs’ world according to GARP. Eur J Immunol 39:3296–3300PubMedCrossRefGoogle Scholar
  103. 103.
    Stockis J, Colau D, Coulie PG, Lucas S (2009) Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol 39:3315–3322PubMedCrossRefGoogle Scholar
  104. 104.
    Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775–787PubMedCrossRefGoogle Scholar
  105. 105.
    Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28–50PubMedCrossRefGoogle Scholar
  106. 106.
    Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, de Waal Malefyt R, de Vries JE, Roncarolo MG (1994) High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 179:493–502PubMedCrossRefGoogle Scholar
  107. 107.
    Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737–742PubMedCrossRefGoogle Scholar
  108. 108.
    Bacchetta R, Sartirana C, Levings MK, Bordignon C, Narula S, Roncarolo MG (2002) Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 32:2237–2245PubMedCrossRefGoogle Scholar
  109. 109.
    Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, Sharpe AH, Karp CL, Miaw SC, Ho IC, Kuchroo VK (2009) Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol 183:797–801PubMedCrossRefGoogle Scholar
  110. 110.
    Haringer B, Lozza L, Steckel B, Geginat J (2009) Identification and characterization of IL-10/IFN-gamma-producing effector-like T cells with regulatory function in human blood. J Exp Med 206:1009–1017PubMedCrossRefGoogle Scholar
  111. 111.
    Carpentier A, Conti F, Stenard F, Aoudjehane L, Miroux C, Podevin P, Morales O, Chouzenoux S, Scatton O, Groux H, Auriault C, Calmus Y, Pancre V, Delhem N (2009) Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am J Transplant 9:2102–2112PubMedCrossRefGoogle Scholar
  112. 112.
    Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ (2004) Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104:2840–2848PubMedCrossRefGoogle Scholar
  113. 113.
    Carosella ED, HoWangYin KY, Favier B, LeMaoult J (2008) HLA-G-dependent suppressor cells: diverse by nature, function, and significance. Hum Immunol 69:700–707PubMedCrossRefGoogle Scholar
  114. 114.
    Gregori S, Magnani CF, Roncarolo MG (2009) Role of human leukocyte antigen-G in the induction of adaptive type 1 regulatory T cells. Hum Immunol 70:966–969PubMedCrossRefGoogle Scholar
  115. 115.
    Le Rond S, Le Maoult J, Creput C, Menier C, Deschamps M, Le Friec G, Amiot L, Durrbach A, Dausset J, Carosella ED, Rouas-Freiss N (2004) Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients. Eur J Immunol 34:649–660PubMedCrossRefGoogle Scholar
  116. 116.
    Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A, Wiendl H (2007) HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 110:568–577PubMedCrossRefGoogle Scholar
  117. 117.
    Huang YH, Zozulya AL, Weidenfeller C, Metz I, Buck D, Toyka KV, Bruck W, Wiendl H (2009) Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis. Ann Neurol 66:171–183PubMedCrossRefGoogle Scholar
  118. 118.
    Huang YH, Zozulya AL, Weidenfeller C, Schwab N, Wiendl H (2009) T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. J Leukoc Biol 86:273–281Google Scholar
  119. 119.
    LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED (2004) HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci USA 101:7064–7069PubMedCrossRefGoogle Scholar
  120. 120.
    Naji A, Durrbach A, Carosella ED, Rouas-Freiss N (2007) Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. Hum Immunol 68:233–239PubMedCrossRefGoogle Scholar
  121. 121.
    Naji A, Le Rond S, Durrbach A, Krawice-Radanne I, Creput C, Daouya M, Caumartin J, LeMaoult J, Carosella ED, Rouas-Freiss N (2007) CD3+ CD4low and CD3+ CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 110:3936–3948PubMedCrossRefGoogle Scholar
  122. 122.
    Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, Hauben E, Roncarolo MG (2010) Differentiation of type 1 T regulatory (Tr1) cells by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116:935–944PubMedCrossRefGoogle Scholar
  123. 123.
    Le Rond S, Azema C, Krawice-Radanne I, Durrbach A, Guettier C, Carosella ED, Rouas-Freiss N (2006) Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol 176:3266–3276PubMedGoogle Scholar
  124. 124.
    Le Maux A, Noel G, Birebent B, Grosset JM, Vu N, De Guibert S, Bernard M, Semana G, Amiot L (2008) Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol 152:50–56PubMedCrossRefGoogle Scholar
  125. 125.
    Horuzsko A, Lenfant F, Munn DH, Mellor AL (2001) Maturation of antigen-presenting cells is compromised in HLA-G transgenic mice. Int Immunol 13:385–394PubMedCrossRefGoogle Scholar
  126. 126.
    Liang S, Baibakov B, Horuzsko A (2002) HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor. Eur J Immunol 32:2418–2426PubMedCrossRefGoogle Scholar
  127. 127.
    Liang S, Horuzsko A (2003) Mobilizing dendritic cells for tolerance by engagement of immune inhibitory receptors for HLA-G. Hum Immunol 64:1025–1032PubMedCrossRefGoogle Scholar
  128. 128.
    Ristich V, Liang S, Zhang W, Wu J, Horuzsko A (2005) Tolerization of dendritic cells by HLA-G. Eur J Immunol 35:1133–1142PubMedCrossRefGoogle Scholar
  129. 129.
    Ristich V, Zhang W, Liang S, Horuzsko A (2007) Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells. Hum Immunol 68:264–271PubMedCrossRefGoogle Scholar
  130. 130.
    Wu J, Zhang W, Hernandez-Lopez P, Fabelo E, Parikh M, Mulloy LL, Horuzsko A (2009) Isoforms of human leukocyte antigen-G and their inhibitory receptors in human kidney allograft acceptance. Hum Immunol 70:988–994PubMedCrossRefGoogle Scholar
  131. 131.
    Gonen-Gross T, Mandelboim O (2007) HLA-G complexes are observed on the cell surface. Hum Immunol 68:227–232PubMedCrossRefGoogle Scholar
  132. 132.
    Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, Kurimoto E, Kato K, Kohda D, Maenaka K (2006) Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA 103:16412–16417PubMedCrossRefGoogle Scholar
  133. 133.
    Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A (2008) Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6–STAT3 signaling pathway. Proc Natl Acad Sci USA 105:8357–8362PubMedCrossRefGoogle Scholar
  134. 134.
    Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R (1990) A class I antigen, HLA-G, expressed in human trophoblasts. Science 248:220–223PubMedCrossRefGoogle Scholar
  135. 135.
    Menier C, Riteau B, Dausset J, Carosella ED, Rouas-Freiss N (2000) HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival. Hum Immunol 61:1118–1125PubMedCrossRefGoogle Scholar
  136. 136.
    Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N (2003) Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 64:315–326PubMedCrossRefGoogle Scholar
  137. 137.
    Khalil-Daher I, Riteau B, Menier C, Sedlik C, Paul P, Dausset J, Carosella ED, Rouas-Freiss N (1999) Role of HLA-G versus HLA-E on NK function: HLA-G is able to inhibit NK cytolysis by itself. J Reprod Immunol 43:175–182PubMedCrossRefGoogle Scholar
  138. 138.
    Riteau B, Menier C, Khalil-Daher I, Sedlik C, Dausset J, Rouas-Freiss N, Carosella ED (1999) HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol 43:203–211PubMedCrossRefGoogle Scholar
  139. 139.
    Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED (2001) HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 166:5018–5026PubMedGoogle Scholar
  140. 140.
    Riteau B, Menier C, Khalil-Daher I, Martinozzi S, Pla M, Dausset J, Carosella ED, Rouas-Freiss N (2001) HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol 13:193–201PubMedCrossRefGoogle Scholar
  141. 141.
    Menier C, Riteau B, Carosella ED, Rouas-Freiss N (2002) MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 100:63–70PubMedCrossRefGoogle Scholar
  142. 142.
    Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED (2005) HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 65:10139–10144PubMedCrossRefGoogle Scholar
  143. 143.
    Jurisicova A, Casper RF, MacLusky NJ, Librach CL (1996) Embryonic human leukocyte antigen-G expression: possible implications for human preimplantation development. Fertil Steril 65:997–1002PubMedGoogle Scholar
  144. 144.
    Jurisicova A, Casper RF, MacLusky NJ, Mills GB, Librach CL (1996) HLA-G expression during preimplantation human embryo development. Proc Natl Acad Sci USA 93:161–165PubMedCrossRefGoogle Scholar
  145. 145.
    Yao YQ, Barlow DH, Sargent IL (2005) Differential expression of alternatively spliced transcripts of HLA-G in human preimplantation embryos and inner cell masses. J Immunol 175:8379–8385PubMedGoogle Scholar
  146. 146.
    Rizzo R, Dal Canto MB, Stignani M, Fadini R, Fumagalli D, Renzini MM, Borgatti M, Gambari R, Baricordi OR (2009) Production of sHLA-G molecules by in vitro matured cumulus-oocyte complex. Int J Mol Med 24:523–530PubMedGoogle Scholar
  147. 147.
    Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss N (2004) Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 104:3153–3160PubMedCrossRefGoogle Scholar
  148. 148.
    Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G (1998) A common precursor for hematopoietic and endothelial cells. Development 125:725–732PubMedGoogle Scholar
  149. 149.
    Bertrand JY, Chi NC, Santoso B, Teng S, Stainier DY, Traver D (2010) Haematopoietic stem cells derive directly from aortic endothelium during development. Nature 464:108–111PubMedCrossRefGoogle Scholar
  150. 150.
    Kissa K, Herbomel P (2010) Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 464:112–115PubMedCrossRefGoogle Scholar
  151. 151.
    Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C (2010) In vivo imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature 464:116–120PubMedCrossRefGoogle Scholar
  152. 152.
    Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N (2008) HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia 22:578–584PubMedCrossRefGoogle Scholar
  153. 153.
    Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, Carosella ED, Charpentier B, Durrbach A (2006) Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 176:1331–1339PubMedGoogle Scholar
  154. 154.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMedGoogle Scholar
  155. 155.
    James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148PubMedCrossRefGoogle Scholar
  156. 156.
    Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790PubMedCrossRefGoogle Scholar
  157. 157.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D’Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397PubMedCrossRefGoogle Scholar
  158. 158.
    Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, Menot ML, Massonnet G, Dutel JL, Ghomari K, Rousselot P, Grange MJ, Chait Y, Vainchenker W, Parquet N, Abdelkader-Aljassem L, Bernard JF, Rain JD, Chevret S, Chomienne C, Fenaux P (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037–2040PubMedCrossRefGoogle Scholar
  159. 159.
    Wagner SN, Rebmann V, Willers CP, Grosse-Wilde H, Goos M (2000) Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 356:220–221PubMedCrossRefGoogle Scholar
  160. 160.
    Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U (2001) Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92:369–376PubMedCrossRefGoogle Scholar
  161. 161.
    Levine RL, Gilliland DG (2008) Myeloproliferative disorders. Blood 112:2190–2198PubMedCrossRefGoogle Scholar
  162. 162.
    Blaschitz A, Lenfant F, Mallet V, Hartmann M, Bensussan A, Geraghty DE, Le Bouteiller P, Dohr G (1997) Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. Eur J Immunol 27:3380–3388PubMedCrossRefGoogle Scholar
  163. 163.
    Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella E, Rouas-Freiss N (2003) HLA-G expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 39:587–594PubMedCrossRefGoogle Scholar
  164. 164.
    Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED (2007) Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 17:413–421PubMedCrossRefGoogle Scholar
  165. 165.
    Menier C, Rouas-Freiss N, Carosella ED (2008) The HLA-G non classical MHC class I molecule is expressed in cancer with poor prognosis. Implications in tumour escape from immune system and clinical applications. In: Atlas of genetics and cytogenetics in oncolology and haematology. Accessed July 2008
  166. 166.
    Tordjman R, Delaire S, Plouët J, Ting S, Gaulard P, Fichelson S, Roméo P-H, Lemarchandel V (2001) Erythroblasts are source of angiogenic factors. Blood 97:1968–1974PubMedCrossRefGoogle Scholar
  167. 167.
    Fons P, Chabot S, Cartwright JE, Lenfant F, L’Faqihi F, Giustiniani J, Herault JP, Gueguen G, Bono F, Savi P, Aguerre-Girr M, Fournel S, Malecaze F, Bensussan A, Plouet J, Le Bouteiller P (2006) Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 108:2608–2615PubMedCrossRefGoogle Scholar
  168. 168.
    Lancrin C, Sroczynska P, Serrano AG, Gandillet A, Ferreras C, Kouskoff V, Lacaud G (2010) Blood cell generation from the hemangioblast. J Mol Med 88:167–172PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2010

Authors and Affiliations

  • Edgardo D. Carosella
    • 1
    • 2
    • 4
  • Silvia Gregori
    • 3
  • Nathalie Rouas-Freiss
    • 1
    • 2
  • Joel LeMaoult
    • 1
    • 2
  • Catherine Menier
    • 1
    • 2
  • Benoit Favier
    • 1
    • 2
  1. 1.CEA, I2BM, Service de Recherches en Hemato-ImmunologieParisFrance
  2. 2.UMR_E, Universite Paris 7IUH, Hopital Saint-LouisParisFrance
  3. 3.Department of Regenerative Medicine, Stem Cells, and Gene TherapySan Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)MilanItaly
  4. 4.CEA-SRHI, Hopital St. LouisParisFrance

Personalised recommendations